CLINICAL TRIALS PROFILE FOR RIBAVIRIN

505(b)(2) Clinical Trials for RIBAVIRIN

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00154869 ↗	Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C	Unknown status	Hoffmann-La Roche	Phase 3	2004-06-01	The investigators' pilot study indicates that hepatitis C virus (HCV)- and hepatitis B virus (HBV)-coinfected patients with predominantly active hepatitis C and those with predominantly active hepatitis B may need different anti-viral regimens. Since in the majority of these coinfected patients the hepatitis activity is more likely due to HCV than to HBV, the optimal therapeutic regimen for HCV- and HBV-coinfected patients with predominantly active hepatitis C will first be investigated. The combination therapy using pegylated interferons (IFNs) such as PEG-IFN alfa-2a has been shown to have a superior efficacy than that using conventional IFN in the treatment of monoinfected chronic hepatitis C. This new combination therapy might also further enhance the treatment efficacy in HCV- and HBV- coinfected patients. The investigators therefore propose to initiate a trial comparing the efficacy of pegylated IFN plus ribavirin (RBV) in dual chronic hepatitis B and C versus that in chronic hepatitis C only, for both HCV genotype 1 and 2/3 patients. The efficacy using a 24-week combination therapy in the sustained clearance of serum HCV RNA is equivalent to that using a 48-week combination therapy in patients with HCV genotype non-1 [Hadziyannis et al, EASL 2002]. A 48-week course of pegylated IFN and RBV combination therapy, in contrast, has been shown to yield a better efficacy in the sustained clearance of serum HCV RNA in patients with HCV genotype 1 than a 24-week combination therapy in western countries [Hadziyannis et al, EASL 2002; Poynard et al, 1998]. The primary objective of the current proposal is to investigate and compare the efficacy of combination therapy using pegylated IFN plus RBV on the clearance of serum HCV RNA in both dually infected patients with a dominant HCV infection and HCV monoinfected patients. Therefore, in this proposal, the treatment duration will be 24 weeks for HCV genotype 2/3 in patients with dual chronic hepatitis C and B and in patients with monoinfected HCV, and will be 48 weeks for HCV genotype 1 in patients with dual chronic hepatitis C and B and in patients with monoinfected HCV.
New Combination	NCT00154869 ↗	Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C	Unknown status	National Taiwan University Hospital	Phase 3	2004-06-01	The investigators' pilot study indicates that hepatitis C virus (HCV)- and hepatitis B virus (HBV)-coinfected patients with predominantly active hepatitis C and those with predominantly active hepatitis B may need different anti-viral regimens. Since in the majority of these coinfected patients the hepatitis activity is more likely due to HCV than to HBV, the optimal therapeutic regimen for HCV- and HBV-coinfected patients with predominantly active hepatitis C will first be investigated. The combination therapy using pegylated interferons (IFNs) such as PEG-IFN alfa-2a has been shown to have a superior efficacy than that using conventional IFN in the treatment of monoinfected chronic hepatitis C. This new combination therapy might also further enhance the treatment efficacy in HCV- and HBV- coinfected patients. The investigators therefore propose to initiate a trial comparing the efficacy of pegylated IFN plus ribavirin (RBV) in dual chronic hepatitis B and C versus that in chronic hepatitis C only, for both HCV genotype 1 and 2/3 patients. The efficacy using a 24-week combination therapy in the sustained clearance of serum HCV RNA is equivalent to that using a 48-week combination therapy in patients with HCV genotype non-1 [Hadziyannis et al, EASL 2002]. A 48-week course of pegylated IFN and RBV combination therapy, in contrast, has been shown to yield a better efficacy in the sustained clearance of serum HCV RNA in patients with HCV genotype 1 than a 24-week combination therapy in western countries [Hadziyannis et al, EASL 2002; Poynard et al, 1998]. The primary objective of the current proposal is to investigate and compare the efficacy of combination therapy using pegylated IFN plus RBV on the clearance of serum HCV RNA in both dually infected patients with a dominant HCV infection and HCV monoinfected patients. Therefore, in this proposal, the treatment duration will be 24 weeks for HCV genotype 2/3 in patients with dual chronic hepatitis C and B and in patients with monoinfected HCV, and will be 48 weeks for HCV genotype 1 in patients with dual chronic hepatitis C and B and in patients with monoinfected HCV.
New Combination	NCT01413490 ↗	Hepatitis C Rimantadine and Antiviral Combination Therapy	Completed	Cancer Research UK		2012-05-01	Hepatitis C virus is one of the leading causes of liver failure and liver cancer worldwide. Current treatment of hepatitis C infection is only successful in about half of those who are eligible. The current treatment aims to boost the host immune system but does not directly act on the virus. Many drugs are in various stages of development that target the virus directly - their specific mode of action is confirmed by showing the virus is forced to adapt in the presence of the drug. As with many viruses, treating with only one specific drug would quickly lead to the virus adapting and becoming resistant. We therefore need to find new combinations of directly acting drugs. Rimantadine has already been shown in the laboratory to target hepatitis C directly. We have designed this study to see if it happens in real life as well. If so, we could use rimantadine to help fight hepatitis c more effectively.
New Combination	NCT01413490 ↗	Hepatitis C Rimantadine and Antiviral Combination Therapy	Completed	The Leeds Teaching Hospitals NHS Trust		2012-05-01	Hepatitis C virus is one of the leading causes of liver failure and liver cancer worldwide. Current treatment of hepatitis C infection is only successful in about half of those who are eligible. The current treatment aims to boost the host immune system but does not directly act on the virus. Many drugs are in various stages of development that target the virus directly - their specific mode of action is confirmed by showing the virus is forced to adapt in the presence of the drug. As with many viruses, treating with only one specific drug would quickly lead to the virus adapting and becoming resistant. We therefore need to find new combinations of directly acting drugs. Rimantadine has already been shown in the laboratory to target hepatitis C directly. We have designed this study to see if it happens in real life as well. If so, we could use rimantadine to help fight hepatitis c more effectively.

All Clinical Trials for RIBAVIRIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000699 ↗	A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic Patients	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	To determine the safety and effectiveness of treatment with ribavirin (RBV) plus isoprinosine (INPX) in preventing the development of AIDS in patients infected with the AIDS virus (HIV). Also to determine the maximal dose of RBV that can be tolerated by HIV-infected patients when RBV is given with INPX. The patients may or may not have generalized lymphadenopathy syndrome (LAS). RBV has prevented the development of AIDS in some HIV-infected patients with LAS and INPX has stimulated the immune system of patients infected with HIV. The immune system fights infections in the human body, and the HIV attacks T cells that are an important part of the immune system. Reports from individual cases treated with both RBV and INPX suggest that clinical improvements occurred in HIV-infected patients, but there is no reliable information on the safety and effectiveness of this drug combination in such patients.
NCT00000733 ↗	Phase I Pharmacokinetic and Tolerance Study of Ribavirin in Human Immunodeficiency Virus (HIV) - Infected Patients	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	To determine how fast ribavirin reaches the bloodstream, what concentration of ribavirin is reached in blood and how long it remains in the blood (pharmacokinetics) when given by different routes of administration. To find the maximum tolerated dose (MTD) of ribavirin. The effects of ribavirin on the immune system, and on the virus will be measured by T4 cell count and p24 antigen levels. Early studies with ribavirin in patients with AIDS and AIDS related complex (ARC) have shown that ribavirin appears to inhibit the spread of the virus. Determination of how much and how often to give the drug will require further knowledge of the pharmacokinetics and toxicity of the drug in patients with AIDS or ARC and in chronic virus carriers who do not have symptoms.
NCT00000772 ↗	A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals	Completed	Bristol-Myers Squibb	Phase 1	1969-12-31	To evaluate the safety and tolerance of concurrent administration of standard-dose didanosine (ddI) with low-dose ribavirin in HIV-positive patients. To determine the pharmacokinetic interactions of concurrent administration of ddI and ribavirin and correlate pharmacokinetic parameters with toxicity. To investigate antiviral activity of the combined regimen. Combination ddI/ribavirin therapy, if safe and effective, offers an alternative combination antiretroviral regimen for patients unable to tolerate regimens containing zidovudine (AZT).
NCT00000772 ↗	A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals	Completed	ICN Pharmaceuticals	Phase 1	1969-12-31	To evaluate the safety and tolerance of concurrent administration of standard-dose didanosine (ddI) with low-dose ribavirin in HIV-positive patients. To determine the pharmacokinetic interactions of concurrent administration of ddI and ribavirin and correlate pharmacokinetic parameters with toxicity. To investigate antiviral activity of the combined regimen. Combination ddI/ribavirin therapy, if safe and effective, offers an alternative combination antiretroviral regimen for patients unable to tolerate regimens containing zidovudine (AZT).
NCT00000772 ↗	A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	To evaluate the safety and tolerance of concurrent administration of standard-dose didanosine (ddI) with low-dose ribavirin in HIV-positive patients. To determine the pharmacokinetic interactions of concurrent administration of ddI and ribavirin and correlate pharmacokinetic parameters with toxicity. To investigate antiviral activity of the combined regimen. Combination ddI/ribavirin therapy, if safe and effective, offers an alternative combination antiretroviral regimen for patients unable to tolerate regimens containing zidovudine (AZT).

Clinical Trial Conditions for RIBAVIRIN

Condition Name

Condition Name for RIBAVIRIN
Intervention	Trials
Hepatitis C	293
Hepatitis C, Chronic	222
Chronic Hepatitis C	197
Hepatitis C Virus	49

Condition MeSH

Condition MeSH for RIBAVIRIN
Intervention	Trials
Hepatitis C	903
Hepatitis	823
Hepatitis A	693
Hepatitis C, Chronic	561

Clinical Trial Locations for RIBAVIRIN

Trials by Country

Trials by Country for RIBAVIRIN
Location	Trials
Canada	372
Brazil	77
New Zealand	73
Taiwan	67
Belgium	65

Trials by US State

Trials by US State for RIBAVIRIN
Location	Trials
Texas	241
California	240
New York	207
Florida	183
Maryland	170

Clinical Trial Progress for RIBAVIRIN

Clinical Trial Phase

Clinical Trial Phase for RIBAVIRIN
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	4

Clinical Trial Status

Clinical Trial Status for RIBAVIRIN
Clinical Trial Phase	Trials
Completed	772
Unknown status	85
Terminated	84

Clinical Trial Sponsors for RIBAVIRIN

Sponsor Name

Sponsor Name for RIBAVIRIN
Sponsor	Trials
Merck Sharp & Dohme Corp.	118
Hoffmann-La Roche	95
Gilead Sciences	76

Sponsor Type

Sponsor Type for RIBAVIRIN
Sponsor	Trials
Other	785
Industry	759
NIH	80

Ribavirin Clinical Trials Update, Market Analysis, and Exclusivity Projection (2026)

Last updated: July 27, 2026

Executive summary: Ribavirin’s clinical program footprint is small versus peak eras, with most current activity concentrated in combination regimens for viral hepatitis and select antiviral targets. Market dynamics remain driven by (1) use as a backbone in curative hepatitis C and hepatitis E contexts historically, (2) replacement by direct-acting antivirals in hepatitis C, and (3) constrained demand that keeps pricing and volumes stable but not growth-oriented. Patent exclusivity is largely historical: ribavirin is an off-patent small molecule in most major markets, so competitive risk is structural rather than event-driven.

---

What is ribavirin’s current clinical trials landscape in 2024–2026?

Ribavirin is an older, broad-spectrum guanosine analog with established combination use historically in hepatitis C virus (HCV), and in some settings for viral hepatitis. As of the current period, trial activity is dominated by combination studies, retrospective registries, and investigator-initiated work that validates dosing, safety, and special-population handling rather than building a new pivotal efficacy package.

Which indications still show active ribavirin clinical evaluation?

• HCV regimens in specific subpopulations: trials and observational studies focus on tolerability and anemia management in patients receiving ribavirin-containing combinations.
• Viral hepatitis outside standard HCV pathways: limited studies evaluate ribavirin-like antiviral strategies and ribavirin use in defined protocols, often where standard-of-care differs by region.
• Combination therapy optimization: dose-ranging work and real-world safety in combinations with other antivirals.

What endpoints and safety issues dominate ribavirin trial reports?

• Hematologic toxicity: anemia is the main safety endpoint and drives dose reductions and discontinuation decisions.
• Dose interruptions and ribavirin exposure-response: maintaining therapeutic exposure while minimizing anemia.
• Renal function strata: ribavirin clearance is renal, so trial reporting typically stratifies by estimated glomerular filtration rate.

Regulatory posture: Ribavirin is not positioned as a new molecular entity. Current clinical activity is best interpreted as refinement and post-approval utilization studies, not as a pipeline engine.

Source (trial search context): ClinicalTrials.gov provides the operative registry view for global trial status. [1]

---

How does ribavirin’s market size and demand profile differ by indication?

Ribavirin demand is inherently fragmented by indication because it is largely displaced in HCV by interferon-free direct-acting antivirals (DAAs). The result is a market that is smaller than historic peaks, with usage concentrated where combination decisions still include ribavirin due to payer rules, drug availability, genotype/clinical edge cases, or cost optimization.

What drives ribavirin sales volume?

• HCV displacement by DAAs: most countries moved from interferon/ribavirin backbones to DAA regimens, reducing ribavirin’s role.
• Residual use cases: ribavirin can still appear in specific combination decisions, often tied to local guidelines and access constraints.
• Geographic variation: ribavirin utilization remains higher in settings where DAA penetration is slower or where formulary decisions favor cheaper older regimens.

What drives pricing and margin profile?

• Generics dominate: multiple manufacturers supply generic ribavirin tablets/capsules/solutions, compressing pricing.
• Acquisition cost sensitivity: buyers manage ribavirin procurement as a cost-controlled commodity.
• Hematology management costs: in combination regimens, anemia monitoring and supportive care increase total treatment cost, but those are usually managed within healthcare systems rather than reflected in ribavirin drug pricing.

---

When does ribavirin lose exclusivity, and what does that mean for generics?

Ribavirin is not expected to have a meaningful exclusivity-driven launch calendar. The compound is off-patent in practice, and generic competition is entrenched. Any “exclusivity” in modern market terms is more likely to relate to specific formulations, local approvals, or historic secondary patents by manufacturer, not to compound-level exclusivity.

What is the practical exclusivity timeline for ribavirin?

• Compound-level exclusivity: elapsed.
• Regulatory exclusivity: ribavirin is not a new active ingredient with contemporary 5-year/3-year exclusivity constructs.
• Key market effect: generics face low patent entry barriers because there is no ongoing broad compound protection.

Source (exclusivity framework context): FDA exclusivity categories apply to NDAs/BLAs and do not create exclusivity for an off-patent generic commodity drug in the same way as new drug approvals. [2]

---

What patents protect ribavirin today, and how strong is the patent estate?

Ribavirin is a generic small molecule with broad availability. Patent estates, where they exist, tend to be:

• older, expired compound claims,
• formulation-specific patents (limited value because multiple approved generics can be outside their scope),
• manufacturing process patents (often not blocking standard commercial manufacturing).

How many active ribavirin patents matter for competition?

For ribavirin as a substance, the actionable number for blocking generic entry is typically low in major markets because supply is already mature and legally cleared by market history.

Source (patent status research approach): Patent status is assessed through national patent databases and Orange Book/NDA-associated listings where applicable. For ribavirin, compound-level exclusivity is not a present driver. [3]

---

What is the Orange Book status of ribavirin?

Ribavirin’s U.S. status is characterized by generic availability. Orange Book listings for ribavirin products generally reflect:

• multiple approved generics,
• expired or non-blocking patent terms,
• limited relevance of any remaining listed patents to new approvals that use already-cleared formulations.

Practical implication: For most buyers, the Orange Book is unlikely to present a barrier to entry that would affect near-term procurement or litigation strategy for ribavirin itself.

Source: FDA’s Orange Book lists patents associated with approved drug products and their expiration dates. [3]

---

Are there Paragraph IV challenges for ribavirin that signal future competition risk?

Given ribavirin’s market maturity and generic dominance, Paragraph IV (P-IV) challenges are not typically the mechanism that changes ribavirin competition. When P-IV filings occur for older drugs, they usually target narrow remaining protections for specific product types or formulations, not the compound.

Market interpretation: Competition risk is structural and continuous, not event-driven by a small number of new P-IV disputes.

Source: FDA’s ANDA framework and the P-IV mechanism are defined by Hatch-Waxman provisions. [2]

---

How does ribavirin compare with direct-acting antivirals (DAAs) in hepatitis C economics?

For HCV, the key competitive comparison is not between ribavirin and a single DAA, but between:

• ribavirin-inclusive regimens (historical backbone, often with interferon or with select combination protocols),
• and interferon-free DAA regimens (current standard-of-care in most markets).

What is the commercial substitution effect?

• Ribavirin is used less because DAAs deliver higher sustained virologic response rates with lower regimen toxicity.
• Ribavirin’s anemia risk raises total management burden in regimens that still include it.
• Payers shifted protocols toward DAA-based cures, reducing ribavirin’s core demand.

Where can ribavirin still appear despite DAA adoption?

• Access-limited geographies where older regimens may remain in formularies.
• Special populations or policy-driven regimen choices where local treatment pathways include ribavirin.

Source (therapeutic standard-of-care context): FDA and guideline ecosystems reflect broad DAA adoption. For clinical and policy context, FDA drug labeling and guideline histories are typically referenced. [2][4]

---

What manufacturing and formulation barriers exist for ribavirin generics?

Ribavirin is not a formulation novelty story. Commercial barriers are typically regulatory and quality-system driven:

• stability for oral products,
• content uniformity and bioavailability consistency,
• sterile manufacturing for any parenteral supply, if used in specific settings.

How do dosing forms affect market supply risk?

• Oral capsules/tablets: easier to maintain stable supply at scale.
• Oral solutions/sterile forms: supply can be more sensitive to manufacturing constraints, but this is not typically a patent-driven barrier.

Source (general regulatory manufacturing expectations): FDA cGMP and ANDA requirements govern generic manufacturing compliance. [2]

---

Which companies supply ribavirin today, and what does the competitive landscape look like?

Ribavirin is a globally supplied generic molecule with multiple suppliers across major markets. Competitive dynamics are defined by:

• procurement contracts,
• supply reliability,
• unit cost,
• ability to support required package sizes and dosing regimens.

How is market competition expressed?

• Low differentiation, high volume competition
• Pricing pressure from multiple ANDA-approved entrants
• Contracting with distributors and institutional formularies

Source: Generic drug competition is evaluated via FDA approvals and market reporting; Orange Book supports the approval landscape. [3]

---

Clinical outcomes and safety: what matters most for ribavirin dosing decisions?

The core clinical value proposition is tied to combination efficacy in specific contexts, while dosing decisions are dominated by safety.

What monitoring patterns drive clinical practice?

• baseline and periodic hemoglobin/hematocrit monitoring,
• renal function assessment due to exposure sensitivity,
• genotype and regimen-specific adjustment protocols (where ribavirin is still used).

Source: Ribavirin labeling includes key safety monitoring requirements. [5]

---

What commercial projections follow from ribavirin’s off-patent status?

With compound exclusivity expired and generics entrenched, projections should focus on:

• volume stability rather than growth,
• potential decline in HCV-associated use as DAAs remain standard,
• localized growth only where DAAs are limited or protocols include ribavirin in defined combination pathways.

Base-case market projection logic

• If HCV treatment remains DAA-dominant: ribavirin demand drifts lower or stays flat.
• If regional access constraints persist: ribavirin can hold steady in those markets.
• If guideline changes reintroduce ribavirin in niche indications: short-term demand spikes are possible but typically do not create durable growth.

---

Key Takeaways

• Ribavirin’s current clinical trial footprint is limited and skewed toward combination optimization, safety, and special-population management rather than new pivotal development.
• The market is generic-commodity driven, with demand declining structurally in HCV as DAAs replace ribavirin-containing regimens.
• Exclusivity is not an event-driven risk for future competition; the compound is effectively off-patent and competitive pressure is continuous.
• The practical competitive battleground is supply reliability, procurement contracting, and formulation/regulatory compliance, not patent barriers.

---

FAQs

1. Is ribavirin still used for hepatitis C in 2026, and in which patient populations?
2. What adverse events most often lead to ribavirin dose reduction or discontinuation?
3. Do any active patents still restrict generic ribavirin tablets or capsules in the U.S.?
4. How does ribavirin renal impairment affect dosing and treatment continuation?
5. What regulatory pathway do generic ribavirin products use in the U.S. (ANDA vs other)?

---

References (APA)

1. ClinicalTrials.gov. (n.d.). Ribavirin search results. https://clinicaltrials.gov/
2. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman Act / ANDA framework and paragraph IV challenges (overview). https://www.fda.gov/
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Orange Book. https://www.accessdata.fda.gov/scripts/cder/daf/
4. U.S. Department of Health and Human Services. (n.d.). HCV treatment guideline resources and updates (historical access via guideline bodies). https://www.hhs.gov/
5. U.S. Food and Drug Administration. (n.d.). Ribavirin product labeling (safety and monitoring sections). https://www.accessdata.fda.gov/scripts/cder/daf/